ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
AZ Fasenra shows benefit in chronic rhinosinusitis with nasal polyps pharmatimes
September 14, 2020AstraZeneca’s Fasenra (benralizumab) significantly reduced the size of nasal polyps and cut nasal blockage in patients with chronic rhinosinusitis, raising hopes for a new treatment option for this condition. -
FDA approves first treatment for chronic rhinosinusitis with nasal polyps biospectrumasia
June 28, 2019Patients who received Dupixent had statistically significant reductions in their nasal polyp size and nasal congestion compared to the placebo group -
FDA Approves Dupixent? for Chronic Rhinosinusitis with Nasal Polyposis americanpharmaceuticalreview
June 27, 2019The U.S. Food and Drug Administration (FDA) has approved Dupixent? (dupilumab) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. CRSwNP can be a debilitating condition ...
Pharma Sources Insight January 2025
